Valneva Completes Lot To Lot Phase 3 Trial Of Single-Shot Chikungunya Vaccine Candidate

Valneva Se, A Specialty Vaccine Company, Announced The Successful Completion Of The Lot-To-Lot Phase 3 Trial Of Its Single-Shot Chikungunya Vaccine Candidate, Vla1553. The Final Analysis Included Six-Month Follow-Up Data And Confirmed The Topline Results Reported In December 2021.The Vla1553-302 Trial Met Its Primary Endpoint, Demonstrating That Three Consecutively Manufactured Vaccine Lots Elicited Equivalent Immune Responses Measured By Neutralizing Antibody Titer Gmt Ratios On Day 29 After Vaccination.The Trial Included 408 Participants Aged 18 To 45 Years. The Safety Profile Shown In Study Vla1553-302 Was Similar To The Phase 3 Trial, Vla1553-301. With A 96.0% Seroprotection Rate At Day 180, The Immunogenicity Profile From Study Vla1553-301 Was Also Confirmed.Juan Carlos Jaramillo, Chief Medical Officer Of Valneva Commented,

Optimize Your trial insights with Clival Database.

Are you exhausted from the uncertainty of trial insights pricing? Clival Database ensures the clarity in the midst of the global scenario for clinical trials to you.

Clival Database is one of the best databases that offers an outstanding number of clinical trial data in terms of 50,000+ molecules and from primary regulatory markets as well as new entrants like Indian and Chinese markets.

With Clival, you get accurate positioning of historical sales data, patent database, company profiling, safety & efficacy, and prediction of launch of new innovative molecules helping you to align your research and driving down the cost.

To add value, we further break down our analytics for you so that improving your operational effectiveness; optimizing your clinical trials; and offering you accurate and high-quality data at lowest possible prices becomes possible.

Elevate your trial success rate with the cutting-edge insights from Clival database.

Check it out today and make more informed sourcing decisions! Learn More!